Cytokeratin 18 knockdown decreases cell migration and increases chemosensitivity in non-small cell lung cancer
Cytokeratin 18 knockdown decreases cell migration and increases chemosensitivity in non-small cell lung cancer
复制标题
细胞角蛋白 18 敲低可减少非小细胞肺癌的细胞迁移并增加化疗敏感性
DOI：
10.1007/s00432-016-2253-x
复制
发表时间：
2016-12-01
影响因子：
3.6
通讯作者：
Wang, Changli
中科院分区：
文献类型：
--
作者：
Zhang, Bin;Wang, Jun;Wang, Changli
细胞角蛋白18（CK 18）是一种结构蛋白，在许多单层上皮细胞中均有表达。以往的研究表明，CK 18的异常表达与癌症的进展有关。然而，CK 18在肺癌中的功能尚未完全阐明。方法采用免疫组织化学方法检测129例非小细胞肺癌（NSCLC）组织芯片中CK 18蛋白的表达，并分析其与临床病理特征及预后的关系。然后，我们研究了CK 18敲低对细胞运动和化疗敏感性在肺癌cells. ResultsCK 18高表达检测101/129（78.3%）肺癌。CK 18表达与临床分期、淋巴结转移、病理阳性淋巴结数及复发转移有关。Kaplan-Meier生存分析显示CK 18是总生存期（P= 0.016）和无病生存期（P= 0.014）的预后因素。此外，CK 18敲低降低细胞迁移和增强肺癌细胞对paclitaxel.ConclusionsThese研究结果表明，CK 18在肺癌的进展中起着重要作用，并可能成为NSCLC的治疗靶点。
PurposeCytokeratin 18 (CK18) is a structural protein that is normally expressed in many single-layer epithelia. Previous studies have indicated that aberrant CK18 expression is associated with cancer progression. However, the functions of CK18 in lung cancer have not been fully elucidated. Here, we investigate the roles of CK18 in non-small cell lung cancer (NSCLC).MethodsCK18 protein expression was evaluated by immunohistochemistry in a lung cancer tissue microarray containing 129 cancer samples, and correlations between CK18 expression and clinicopathological characteristics and prognosis were analyzed. We then studied the effects of CK18 knockdown on cell motility and chemosensitivity in lung cancer cells.ResultsHigh CK18 expression was detected in 101/129 (78.3 %) lung cancers. CK18 expression was significantly correlated to clinical stage, lymph node metastasis, the number of pathologically positive lymph nodes and recurrence and metastasis. Kaplan–Meier survival analysis showed that CK18 was a prognostic factor for overall survival (P= 0.016) and disease-free survival (P= 0.014). In addition, CK18 knockdown decreased cell migration and enhanced the sensitivity of lung cancer cells to paclitaxel.ConclusionsThese findings indicate that CK18 plays an important role in lung cancer progression and may be a therapeutic target for NSCLC.